- Home
- MYGN vs ISD Comparison
MYGN vs ISD Comparison
Compare MYGN & ISD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- ISD
- Stock Information
- Founded
- MYGN 1991
- ISD 2012
- Country
- MYGN United States
- ISD United States
- Employees
- MYGN N/A
- ISD N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ISD Trusts Except Educational Religious and Charitable
- Sector
- MYGN Health Care
- ISD Finance
- Exchange
- MYGN Nasdaq
- ISD Nasdaq
- Market Cap
- MYGN 423.1M
- ISD 472.3M
- IPO Year
- MYGN 1995
- ISD N/A
- Fundamental
- Price
- MYGN $3.91
- ISD $14.29
- Analyst Decision
- MYGN Hold
- ISD
- Analyst Count
- MYGN 15
- ISD 0
- Target Price
- MYGN $15.14
- ISD N/A
- AVG Volume (30 Days)
- MYGN 1.3M
- ISD 127.1K
- Earning Date
- MYGN 08-12-2025
- ISD 01-01-0001
- Dividend Yield
- MYGN N/A
- ISD 9.69%
- EPS Growth
- MYGN N/A
- ISD N/A
- EPS
- MYGN N/A
- ISD N/A
- Revenue
- MYGN $831,300,000.00
- ISD N/A
- Revenue This Year
- MYGN N/A
- ISD N/A
- Revenue Next Year
- MYGN $6.64
- ISD N/A
- P/E Ratio
- MYGN N/A
- ISD N/A
- Revenue Growth
- MYGN 7.38
- ISD N/A
- 52 Week Low
- MYGN $3.78
- ISD $10.98
- 52 Week High
- MYGN $29.30
- ISD $13.17
- Technical
- Relative Strength Index (RSI)
- MYGN 30.48
- ISD 60.98
- Support Level
- MYGN $4.43
- ISD $14.01
- Resistance Level
- MYGN $4.83
- ISD $14.14
- Average True Range (ATR)
- MYGN 0.25
- ISD 0.10
- MACD
- MYGN -0.10
- ISD 0.01
- Stochastic Oscillator
- MYGN 9.32
- ISD 74.36
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About ISD PGIM High Yield Bond Fund Inc.
PGIM High Yield Fund Inc is a diversified, closed-end management investment company, active in the financial services domain. The Fund's investment objective is to provide a high level of current income. It invests at least 80% of its investable assets in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments.